Generate Biomedicines and Zealand Pharma enter collaboration to develop AI-engineered protein therapeutics
ZEAL•Generate Biomedicines and Zealand Pharma will develop protein therapeutics for obesity and metabolic diseases. Generate will receive $30 million upfront, up to $1.20 billion in milestones and royalties.
1. Collaboration terms
Generate Biomedicines will lead research under the agreement, while Zealand Pharma will handle clinical development and commercialization.
